Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-12-10 pm EST 		5-day change 1st Jan Change
92.34 USD +1.93% Intraday chart for Gilead Sciences, Inc. -0.16% +13.99%
Dec. 10 Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says MT
Dec. 10 Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating MT

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says
Dec. 10
 MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating
Dec. 10
 MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Keeps Outperform Rating
Dec. 10
 MT
Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy
Dec. 09
 MT
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
Dec. 09
 BU
Kite, Gilead Company, Announces Results from Five-Year Follow-Up Analysis of ZUMA-5, Phase 2 Study of Yescarta in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas Including Follicular Lymphoma or Marginal Zone Lymphoma
Dec. 09
 CI
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Dec. 09
 BU
Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition
Dec. 09
 CI
Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH
Dec. 08
 CI
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
Dec. 08
 BU
Gilead Sciences Seeks Small Acquisitions
Dec. 04
 CI
Gilead Sciences, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 11:40 AM
Dec. 04
HSBC Adjusts Price Target on Gilead Sciences to $82 From $69
Dec. 04
 MT
Gilead Sciences Insider Sold Shares Worth $23,065,271, According to a Recent SEC Filing
Dec. 03
 MT
Gilead Sciences, Inc. Presents at Piper Sandler 36th Annual Healthcare Conference, Dec-03-2024 11:00 AM
Dec. 03
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors
Dec. 03
 MT
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Dec. 03
 BU
Gilead Sciences, Inc. and Tubulis Enter into Exclusive Option and License Agreement to Discover and Develop Antibody-Drug Conjugate Against Solid Tumor Target
Dec. 03
 CI
European Commission Secures 2.3 Million Doses of Gilead's COVID-19 Drug
Dec. 02
 MT
Jefferies Raises Price Target on Gilead Sciences to $115 From $105
Dec. 02
 MT
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Nov. 27
 BU
Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Nov. 27
 CI
Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic
Nov. 26
 AQ
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.
Nov. 25
 AQ
UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating
Nov. 22
 MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.